The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback